Core Viewpoint - The article highlights the challenges faced by patients with myasthenia gravis, a rare autoimmune disease, including misdiagnosis, treatment difficulties, and the need for better healthcare support and awareness [1][4][11]. Group 1: Patient Challenges - Patients with myasthenia gravis often experience symptoms such as sudden weakness, drooping eyelids, and difficulty swallowing, leading to misdiagnosis as psychological issues or other conditions [3][4]. - The prevalence of myasthenia gravis is approximately 7.4 per million people, translating to around 650,000 patients in China due to the large population [4][7]. - Many patients report being misdiagnosed for years, which delays appropriate treatment and exacerbates their condition [3][4]. Group 2: Treatment and Healthcare Support - Current treatments for myasthenia gravis include cholinesterase inhibitors, corticosteroids, and immunosuppressants, but many essential medications are not covered by insurance, leading to high out-of-pocket costs [7][8]. - The new national medical insurance drug list, effective January 1, 2024, includes two medications for myasthenia gravis, but patients still face significant financial burdens for ongoing and crisis treatments [7][8]. - Experts suggest that myasthenia gravis should be included in outpatient chronic disease categories to improve reimbursement rates and access to necessary medications [8][9]. Group 3: Psychological and Social Aspects - The psychological impact of myasthenia gravis is significant, with many patients facing discrimination and social stigma due to visible symptoms like drooping eyelids [11]. - A study indicated that 17.1% of surveyed patients experienced discrimination affecting their work and study opportunities, highlighting the need for greater societal awareness and support [11]. - Mental health support is emphasized as a crucial component of treatment, alongside physical health interventions [11].